Jean-Louis Laplanche

List of Publications by Year
in descending order

87 papers	3,983 citations	101543 36 h-index	128289 60 g-index
90 all docs	90 docs citations	90 times ranked	5381 citing authors

#	Article	IF	Citations
1	Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview. Alzheimer's and Dementia, 2022, 18, 1868-1879.	0.8	26
2	An in vivo Caenorhabditis elegans model for therapeutic research in human prion diseases. Brain, 2021, 144, 2745-2758.	7.6	3
3	Clustering suicidal phenotypes and genetic associations with brain-derived neurotrophic factor in patients with substance use disorders. Translational Psychiatry, 2021, 11, 72.	4.8	4
4	POLR1B and neural crest cell anomalies in Treacher Collins syndrome type 4. Genetics in Medicine, 2020, 22, 547-556.	2.4	63
5	Cerebrospinal fluid A beta 1â€“40 peptides increase in Alzheimerâ€™s disease and are highly correlated with phospho-tau in control individuals. Alzheimer's Research and Therapy, 2020, 12, 123.	6.2	33
6	A novel deep intronic variant in ATP7B in five unrelated families affected by Wilson disease. Molecular Genetics & Genomic Medicine, 2020, 8, e1428.	1.2	8
7	Identification of novel risk loci and causal insights for sporadic Creutzfeldt-Jakob disease: a genome-wide association study. Lancet Neurology, The, 2020, 19, 840-848.	10.2	42
8	Age and the association between apolipoprotein E genotype and Alzheimer disease: A cerebrospinal fluid biomarkerâ€“based caseâ€“control study. PLoS Medicine, 2020, 17, e1003289.	8.4	39
9	Translational study of the whole transcriptome in rats and genetic polymorphisms in humans identifies LRP1B and VPS13A as key genes involved in tolerance to cocaine-induced motor disturbances. Translational Psychiatry, 2020, 10, 381.	4.8	6
10	The neurobehavioral effects of the designer drug naphyrone â€“ an experimental investigation with pharmacokinetics and concentration/effect relationship in mice. Psychopharmacology, 2020, 237, 1943-1957.	3.1	4
11	Title is missing!. , 2020, 17, e1003289.		0
12	Title is missing!. , 2020, 17, e1003289.		0
13	Title is missing!. , 2020, 17, e1003289.		0
14	Title is missing!. , 2020, 17, e1003289.		0
15	Title is missing!. , 2020, 17, e1003289.		0
16	Title is missing!. , 2020, 17, e1003289.		0
17	Title is missing!. , 2020, 17, e1003289.		0
18	QT length during methadone maintenance treatment: geneÂÃ—Âdose interaction. Fundamental and Clinical Pharmacology, 2019, 33, 96-106.	1.9	10

#	Article	IF	Citations
19	Is the 3,4-methylendioxypyrovalerone/mephedrone combination responsible for enhanced stimulant effects? A rat study with investigation of the effect/concentration relationships. Psychopharmacology, 2019, 236, 891-901.	3.1	5
20	Age at onset in genetic prion disease and the design of preventive clinical trials. Neurology, 2019, 93, e125-e134.	1.1	73
21	Biomarker profiles of Alzheimerâ€™s disease and dynamic of the association between cerebrospinal fluid levels of Î²-amyloid peptide and tau. PLoS ONE, 2019, 14, e0217026.	2.5	18
22	Autosomal recessive Treacher Collins syndrome due to POLR1C mutations: Report of a new family and review of the literature. American Journal of Medical Genetics, Part A, 2019, 179, 1390-1394.	1.2	19
23	CSF level of Î²-amyloid peptide predicts mortality in Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2019, 11, 29.	6.2	19
24	Acute and chronic neurobehavioral effects of the designer drug and bath salt constituent 3,4-methylenedioxypyrovalerone in the rat. Journal of Psychopharmacology, 2019, 33, 392-405.	4.0	21
25	Distribution of Cerebrospinal Fluid Biomarker Profiles in Patients Explored forÂCognitive Disorders. Journal of Alzheimer's Disease, 2018, 64, 889-897.	2.6	9
26	High genetic carrier frequency of Wilsonâ€™s disease in France: discrepancies with clinical prevalence. BMC Medical Genetics, 2018, 19, 143.	2.1	47
27	Relevance of Follow-Up in Patients with Core Clinical Criteria for Alzheimer Disease and Normal CSF Biomarkers. Current Alzheimer Research, 2018, 15, 691-700.	1.4	5
28	Neurobehavioral effects of lithium in the rat: Investigation of the effect/concentration relationships and the contribution of the poisoning pattern. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2017, 76, 124-133.	4.8	9
29	Region-specific protein misfolding cyclic amplification reproduces brain tropism of prion strains. Journal of Biological Chemistry, 2017, 292, 16688-16696.	3.4	6
30	Accuracy of diagnosis criteria in patients with suspected diagnosis of sporadic Creutzfeldt-Jakob disease and detection of 14-3-3 protein, France, 1992 to 2009. Eurosurveillance, 2017, 22, .	7.0	20
31	Differential Diagnosis of Dementia with High Levels of Cerebrospinal Fluid Tau Protein. Journal of Alzheimer's Disease, 2016, 51, 905-913.	2.6	21
32	Detection of prions in the plasma of presymptomatic and symptomatic patients with variant Creutzfeldt-Jakob disease. Science Translational Medicine, 2016, 8, 370ra182.	12.4	114
33	Mechanisms of tramadol-related neurotoxicity in the rat: Does diazepam/tramadol combination play a worsening role in overdose?. Toxicology and Applied Pharmacology, 2016, 310, 108-119.	2.8	40
34	Quantifying prion disease penetrance using large population control cohorts. Science Translational Medicine, 2016, 8, 322ra9.	12.4	289
35	Variability of response to methadone: genome-wide DNA methylation analysis in two independent cohorts. Epigenomics, 2016, 8, 181-195.	2.1	17
36	Treacher Collins syndrome: a clinical and molecular study based on a large series of patients. Genetics in Medicine, 2016, 18, 49-56.	2.4	125

#	Article	IF	Citations
37	Validation of 14-3-3 Protein as a Marker in Sporadic Creutzfeldt-Jakob Disease Diagnostic. Molecular Neurobiology, 2016, 53, 2189-2199.	4.0	80
38	A cannabinoid receptor 1 polymorphism is protective against major depressive disorder in methadoneâ€maintained outpatients. American Journal on Addictions, 2015, 24, 613-620.	1.4	23
39	Cerebrospinal fluid amyloid-Î² 42/40 ratio in clinical setting of memory centers: a multicentric study. Alzheimer's Research and Therapy, 2015, 7, 30.	6.2	101
40	Methadone dose in heroinâ€dependent patients: role of clinical factors, comedications, genetic polymorphisms and enzyme activity. British Journal of Clinical Pharmacology, 2015, 79, 967-977.	2.4	57
41	Increased levels of cerebrospinal fluid JNK3 associated with amyloid pathology: links to cognitive decline. Journal of Psychiatry and Neuroscience, 2015, 40, 151-161.	2.4	75
42	Genotyping Test with Clinical Factors: Better Management of Acute Postoperative Pain?. International Journal of Molecular Sciences, 2015, 16, 6298-6311.	4.1	12
43	A diagnostic scale for Alzheimerâ€™s disease based on cerebrospinal fluid biomarker profiles. Alzheimer's Research and Therapy, 2014, 6, 38.	6.2	44
44	Impact of harmonization of collection tubes on Alzheimer's disease diagnosis. , 2014, 10, S390-S394.e2.		58
45	Large deletions encompassing the TCOF1 and CAMK2A genes are responsible for Treacher Collins syndrome with intellectual disability. European Journal of Human Genetics, 2014, 22, 52-56.	2.8	22
46	Doxycycline in Creutzfeldt-Jakob disease: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurology, The, 2014, 13, 150-158.	10.2	157
47	The screening of Alzheimerâ€™s patients with CSF biomarkers, modulates the distribution of APOE genotype: impact on clinical trials. Journal of Neurology, 2014, 261, 1187-1195.	3.6	11
48	KCNH2 polymorphism and methadone dosage interact to enhance QT duration. Drug and Alcohol Dependence, 2014, 141, 34-38.	3.2	18
49	Exacerbated CSF abnormalities in younger patients with Alzheimer's disease. Neurobiology of Disease, 2013, 54, 486-491.	4.4	14
50	CSF biomarker variability in the Alzheimer's Association quality control program. Alzheimer's and Dementia, 2013, 9, 251-261.	0.8	344
51	Intersite variability of CSF Alzheimer's disease biomarkers in clinical setting. Alzheimer's and Dementia, 2013, 9, 406-413.	0.8	63
52	Pharmacogenetics of opiates in clinical practice: the visible tip of the iceberg. Pharmacogenomics, 2013, 14, 575-585.	1.3	37
53	Impact of the 2008â€“2012 French Alzheimer Plan on the Use of Cerebrospinal Fluid Biomarkers in Research Memory Center: The PLM Study. Journal of Alzheimer's Disease, 2013, 34, 297-305.	2.6	51
54	Cerebrospinal Fluid PKR Level Predicts Cognitive Decline in Alzheimerâ€™s Disease. PLoS ONE, 2013, 8, e53587.	2.5	46

#	Article	IF	Citations
55	Glycoform-Selective Prion Formation in Sporadic and Familial Forms of Prion Disease. PLoS ONE, 2013, 8, e58786.	2.5	32
56	Cerebrospinal fluid biomarker supported diagnosis of Creutzfeldtâ€“Jakob disease and rapid dementias: a longitudinal multicentre study over 10 years. Brain, 2012, 135, 3051-3061.	7.6	135
57	Substitutions at residue 211 in the prion protein drive a switch between CJD and GSS syndrome, a new mechanism governing inherited neurodegenerative disorders. Human Molecular Genetics, 2012, 21, 5417-5428.	2.9	29
58	Genome-wide study links MTMR7 gene to variant Creutzfeldt-Jakob risk. Neurobiology of Aging, 2012, 33, 1487.e21-1487.e28.	3.1	40
59	Increased Cerebrospinal Fluid Levels of Double-Stranded RNA-Dependant Protein Kinase in Alzheimer's Disease. Biological Psychiatry, 2012, 71, 829-835.	1.3	52
60	Epidemiogenetic study of French families with Paget's disease of bone. Joint Bone Spine, 2012, 79, 393-398.	1.6	31
61	Inverse association between CSF AÎ² 42 levels and years of education in mild form of Alzheimer's disease: The cognitive reserve theory. Neurobiology of Disease, 2010, 40, 456-459.	4.4	30
62	Neuron Dysfunction Is Induced by Prion Protein with an Insertional Mutation via a Fyn Kinase and Reversed by Sirtuin Activation inCaenorhabditis elegans. Journal of Neuroscience, 2010, 30, 5394-5403.	3.6	51
63	Rare E196K mutation in the PRNP gene of a patient exhibiting behavioral abnormalities. Clinical Neurology and Neurosurgery, 2010, 112, 244-247.	1.4	7
64	Variant Creutzfeldtâ€“Jakob disease in France and the United Kingdom: Evidence for the same agent strain. Annals of Neurology, 2009, 65, 249-256.	5.3	67
65	Loss of Cerebellar Granule Neurons Is Associated With Punctate but Not With Large Focal Deposits of Prion Protein in Creutzfeldt-Jakob Disease. Journal of Neuropathology and Experimental Neurology, 2009, 68, 892-901.	1.7	9
66	Human prion diseases: from antibody screening to a standardized fast immunodiagnosis using automation. Modern Pathology, 2008, 21, 140-149.	5.5	12
67	V180I mutation of the prion protein gene associated with atypical PrPSc glycosylation. Neuroscience Letters, 2006, 408, 165-169.	2.1	43
68	Paget's Disease of Bone in the French Population: Novel SQSTM1 Mutations, Functional Analysis, and Genotype-Phenotype Correlations. Journal of Bone and Mineral Research, 2006, 22, 310-317.	2.8	67
69	Genetics ofÂPagetâ€™s disease ofÂbone. Joint Bone Spine, 2006, 73, 243-248.	1.6	45
70	Striking PrPscheterogeneity in inherited prion diseases with the D178N mutation. Annals of Neurology, 2004, 56, 910-911.	5.3	17
71	The Human â€œPrion-likeâ€•Protein Doppel Is Expressed in Both Sertoli Cells and Spermatozoa. Journal of Biological Chemistry, 2002, 277, 43071-43078.	3.4	75
72	Serotonin transporter gene polymorphism influences age at onset in patients with bipolar affective disorder. Neuroscience Letters, 2002, 334, 17-20.	2.1	53

#	Article	IF	Citations
73	Determination of 14â€“3â€“3 protein levels in cerebrospinal fluid from Creutzfeldtâ€“Jakob patients by a highly sensitive capture assay. Neuroscience Letters, 2001, 301, 167-170.	2.1	28
74	Serotonin transporter gene polymorphism and psychiatric disorders in NF1 patients. American Journal of Medical Genetics Part A, 2001, 105, 758-760.	2.4	2
75	Distribution of the M129V polymorphism of the prion protein gene in a Turkish population suggests a high risk for Creutzfeldt-Jakob disease. European Journal of Human Genetics, 2001, 9, 965-968.	2.8	31
76	Identification of three novel mutations (E196K, V203I, E211Q) in the prion protein gene (PRNP) in inherited prion diseases with Creutzfeldt-Jakob disease phenotype. Human Mutation, 2000, 15, 482-482.	2.5	87
77	PrP immunohistochemistry: Different protocols, including a procedure for long formalin fixation, and a proposed schematic classification for deposits in sporadic Creutzfeldt-Jakob disease. Microscopy Research and Technique, 2000, 50, 26-31.	2.2	23
78	Novel approaches in diagnosis and therapy of Creutzfeldtâ€“Jakob disease. Mechanisms of Ageing and Development, 2000, 116, 193-218.	4.6	41
79	First report of polymorphisms in the prion-like protein gene (PRND): implications for human prion diseases. Neuroscience Letters, 2000, 286, 144-148.	2.1	73
80	Possible association between serotonin transporter gene polymorphism and violent suicidal behavior in mood disorders. Biological Psychiatry, 2000, 48, 319-322.	1.3	143
81	Prominent psychiatric features and early onset in an inherited prion disease with a new insertional mutation in the prion protein gene. Brain, 1999, 122, 2375-2386.	7.6	83
82	Mutation at codon 210 (V210I) of the prion protein gene in a North African patient with Creutzfeldt-Jakob disease. Journal of the Neurological Sciences, 1999, 168, 141-144.	0.6	23
83	Cluster of Creutzfeldt-Jakob disease in France associated with the codon 200 mutation (E200K) in the prion protein gene. European Journal of Neurology, 1998, 5, 375-379.	3.3	10
84	Serotonin transporter gene polymorphisms in patients with unipolar or bipolar depression. Neuroscience Letters, 1998, 255, 143-146.	2.1	123
85	Serotonin transporter gene and manic depressive illness: An association study. Biological Psychiatry, 1997, 41, 750-752.	1.3	59
86	Deletions in the prion protein gene are not associated with CJD. Human Molecular Genetics, 1993, 2, 541-544.	2.9	97
87	Deletion in prion protein gene in a Moroccan family. Nucleic Acids Research, 1990, 18, 6745-6745.	14.5	55